The Top 5 Biosimilars Articles for the Week of January 15

The Center for Biosimilars Staff

The Center for Biosimilars recaps the top 5 biosimilars articles for the week of January 15, 2018.

Transcript:

Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of January 15.

Number 5: The United Kingdom’s Medicines and Healthcare Products Regulatory Agency announced that it will not make any sudden changes to the nation’s regulatory framework following Brexit.

Number 4: A newly published study found that pediatric patients with Crohn disease who received early combination therapy with infliximab and azathioprine had significantly increased linear growth compared with patients who received step-up therapy.

Number 3: Several European nations are amending their policies in order to create better conditions for biosimilar uptake.

Number 2: Sandoz announced that the FDA has accepted its Biologics License Application for a proposed adalimumab biosimilar.

Number 1: The Medicare Payment Advisory Commission called for changes to Medicare Part D to remove financial disincentives that block the use of lower-cost biosimilar therapies.

Finally, last week, our e-newsletter asked whether you think that Congress should revisit legislative solutions to the problem of high drug prices. To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.